| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFRSF19L |
| Uniprot No | Q969Z4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-160aa |
| 氨基酸序列 | STTLWQCPPGEEPDLDPGQGTLCRPCPPGTFSAAWGSSPCQPHARCSLWR RLEAQVGMATRDTLCGDCWPGWFGPWGVPRVPCQPCSWAPLGTHGCDEWG RRARRGVEVAAGASSGGETRQPGNGTRAGGPEETAVDDIEGRMDEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK |
| 预测分子量 | 41 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFRSF19L重组蛋白的参考文献示例(内容为模拟概括，非真实文献)：
1. **文献名称**: *Functional characterization of TNFRSF19L in immune regulation*
**作者**: Zhang Y, et al.
**摘要**: 研究通过重组TNFRSF19L蛋白体外实验，发现其能激活NF-κB信号通路，并促进T细胞增殖，提示其在适应性免疫应答中的潜在作用。
2. **文献名称**: *Recombinant TNFRSF19L protein induces apoptosis in cancer cells*
**作者**: Lee S, et al.
**摘要**: 利用大肠杆菌表达系统纯化TNFRSF19L重组蛋白，体外实验显示其通过结合TRAIL配体触发肿瘤细胞凋亡，为靶向治疗提供新思路。
3. **文献名称**: *Structural analysis of TNFRSF19L and its ligand interaction*
**作者**: Chen X, et al.
**摘要**: 通过X射线晶体学解析TNFRSF19L重组蛋白的胞外结构域，揭示其与未知配体的结合模式，为受体功能机制研究奠定基础。
4. **文献名称**: *TNFRSF19L modulates Wnt signaling in neural development*
**作者**: Wang H, et al.
**摘要**: 研究利用重组TNFRSF19L蛋白处理神经干细胞，发现其通过抑制Wnt/β-catenin通路影响神经元分化，提示其在神经系统发育中的调控作用。
注：以上文献为示例，实际研究中请结合具体数据库(如PubMed、Google Scholar)检索最新成果。
TNFRSF19L (tumor necrosis factor receptor superfamily member 19-like) is a less-characterized member of the TNF receptor superfamily, which plays critical roles in regulating cellular processes such as apoptosis, inflammation, and immune responses. Structurally, it contains conserved cysteine-rich domains typical of TNF receptors, along with a putative intracellular death domain, suggesting involvement in pro-apoptotic signaling pathways. TNFRSF19L shares homology with TNFRSF19 (also called TROY or TAJ), but its distinct expression patterns and functional divergence imply unique biological roles. While TNFRSF19 is implicated in neural development and cancer progression, TNFRSF19L remains understudied, though emerging evidence links it to immune modulation and tissue homeostasis.
Recombinant TNFRSF19L protein is typically produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, followed by affinity purification. This engineered protein enables functional studies to delineate its interactions with potential ligands, such as TNF-related cytokines, and downstream signaling mechanisms. Research applications include investigating its role in cell survival, differentiation, and crosstalk with pathways like NF-κB or JNK. Notably, TNFRSF19L has been observed in specific immune cell subsets and epithelial tissues, hinting at context-dependent functions in mucosal immunity or barrier integrity. Its dysregulation has been tentatively associated with inflammatory diseases and certain malignancies, positioning it as a potential therapeutic target or biomarker. Further characterization of recombinant TNFRSF19L is essential to clarify its physiological relevance and translational potential.
×
